<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328262</url>
  </required_header>
  <id_info>
    <org_study_id>2010/476</org_study_id>
    <nct_id>NCT01328262</nct_id>
  </id_info>
  <brief_title>A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching</brief_title>
  <official_title>A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate whether the targeted hemoglobin increment (2 grams per&#xD;
      decilitre) in the patient can be predicted from the hemoglobin dose/weight of the blood bag&#xD;
      transfused. In the test group, the hemoglobin dose needed will be calculated, whereas in the&#xD;
      control group, the prescribed number of red cell units will be transfused.&#xD;
&#xD;
      Hypothesis: By matching the hemoglobin dose to the individual needs of the patient the&#xD;
      investigators will reduce the total usage of red cell concentrates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized clinical study on hemoglobin dose and patient matching. The aim of the&#xD;
      study is to evaluate whether the targeted hemoglobin increment (2 grams per decilitre) in the&#xD;
      patient can be predicted from the hemoglobin dose/weight of the blood bag transfused. In the&#xD;
      test group, the hemoglobin dose needed will be calculated, whereas in the control group, the&#xD;
      prescribed number of red cell units will be transfused.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Few patients, time consuming to find suiting blood bags with the &quot;right&quot; weight.&#xD;
  </why_stopped>
  <start_date type="Actual">November 2010</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin value</measure>
    <time_frame>Less than 24 hours before transfusion and immediately after transfusion</time_frame>
    <description>The investigators measure the hemoglobin levels before and after transfusion to see if the hemoglobin increment is as expected from the amount of red cells given.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Hemoglobin dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Calculated red blood cell transfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Standard red blood cell transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Calculated red blood cell transfusion</intervention_name>
    <description>The subjects receive an amount of red blood cells that has been calculated from their body surface area.</description>
    <arm_group_label>Hemoglobin dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard red blood cell transfusion</intervention_name>
    <description>The subjects in this group receive the prescribed number of red blood cell units.</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving red cell transfusions or expected to receive one or more red cell&#xD;
             transfusions&#xD;
&#xD;
          -  Patients over 16 years of age&#xD;
&#xD;
          -  Patients for whom height and weight information is available&#xD;
&#xD;
          -  Patients who have consented to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are hemodynamically unstable (ongoing bleeding or hemolysis)&#xD;
&#xD;
          -  Patients with a known hemolytic anemia (congenital or acquired)&#xD;
&#xD;
          -  Patients with a positive Direct Antiglobulin Test (DAT)&#xD;
&#xD;
          -  Patients for whom informed consent has not been obtained&#xD;
&#xD;
          -  Patients where the hemoglobin concentration increment target is above 2g/dl.&#xD;
&#xD;
          -  Patients with auto- or alloantibodies against RBCs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tor A Hervig, Professor</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemoglobins</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

